Compare Roundhill Magnificent Seven ETF (MAGS) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs 10X Genomics Inc — how do they compare? Roundhill Magnificent Seven ETF trades at $66.74, while 10X Genomics Inc trades at $47.2 (market cap $5.48B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, Roundhill Magnificent Seven ETF nearer its low. Which is the better fit depends on your goals.
| MAGS | TXG | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.94 | $45.80 |
52-Week Low | $55.39 | $11.34 |
Market Cap | — | $5.48B |
Enterprise Value | — | $5.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS (Roundhill Magnificent Seven ETF) trades at $66.93, showing minimal daily movement with a 0.03% gain. The ETF provides equal-weighted exposure to seven mega-cap tech stocks dominating AI-driven market returns. Technical indicators show mixed signals with bullish moving averages but neutral oscillators, while support and resistance cluster tightly around $66-68. Recent performance has been volatile, with the ETF dropping from its 2026 high of $71.17 amid sector rotation concerns.
The outlook hinges on AI adoption timelines and hyperscaler profitability. While MAGS delivered 181% returns since launch, concentration risk and high expectations create vulnerability if AI profits materialize slower than anticipated. Near-term performance depends on Q2 earnings broadening beyond semiconductors to Big Tech, with Morgan Stanley noting potential pivot opportunities. Current valuation compression in hyperscalers could present entry points if AI revenue outpaces infrastructure costs.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
